Clinical Characteristics of Patients Responding to Once-Daily Basal Insulin Therapy in Korean Subjects with Type 2 Diabetes

Abstract

IntroductionA1chieve® (ClinicalTrials.gov identifier NCT00869908) was a 24-week observational study evaluating certain insulin analogs and not insulin analogs in general in 66,726 people with type 2 diabetes (T2D) in routine clinical care in 28 non-Western countries. This study demonstrated that insulin analogs improved self-management and metabolic control in patients with T2D. We investigated the effectiveness and clinical characteristics of patients with T2D showing better response to basal insulin (BI) (detemir), using data from the A1chieve study performed in Korea.MethodsSubjects were classified into two groups according to the achievement of target glycated hemoglobin (A1c) level of <7.5%. Multivariate logistic regression analysis was performed to determine the variables independently associated with the achievement of target A1c level.ResultsBaseline A1c, postprandial glucose (PPG), difference between PPG and fasting plasma glucose, and duration of diabetes were independently associated with better response to BI after adjusting for other risk factors. Compared to patients with BI use at evening, those who took BI in the morning demonstrated a larger reduction in A1c level.ConclusionOnce-daily BI therapy appears to be effective in Korean subjects with type 2 diabetes who had a shorter duration of diabetes and a smaller postprandial glucose excursion.FundingNovo Nordisk Pharma Korea and Novo Nordisk International Operations.Electronic supplementary materialThe online version of this article (doi:10.1007/s13300-015-0140-0) contains supplementary material, which is available to authorized users.

Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide

“…For diabetic patients, the level of glycated albumin can be two-to three-fold higher compared to in healthy people (19,20). This increased glycation rate of albumin could explain the difference in efficiency of fattyacid grafted drugs observed in some patients suffering from advanced forms of diabetes (21). In this work, 19 F NMR transverse relaxation time experiments were used to investigate how albumin glycation influences its binding properties to liraglutide.…”

The Characteristics of Patients whose both Fasting and Postprandial Glucose were Controlled by Once Daily Basal Insulin Monotherapy

“…Compared to a sub-analysis of Koreans in a large observational study, the percentage of patients taking concomitant OAD with basal insulin was 83.79% [15]. That result may represent about 17% of patients taking basal insulin and who do not take any OAD in real practice.…”

“…A recent paper confirming the predictive factors of insulin analog user in 28 different countries reported that a higher baseline A1c was the most powerful predictor for lower final A1c [16], but sub-analysis of Korean patients showed better response in patients who had lower A1c [15]. Our study was conducted to stop all background OHA and initiate and adjust insulin dosage to reach an optimal FPG goal, which differs from studies that added insulin as a background OHA.…”

Albumin Binds COVID-19 Spike 1 Subunit and Predicts In-Hospital Survival of Infected Patients—Possible Alteration by Glucose

“…Any conformational change to albumin can affect its binding affinity to other molecules, including viruses. In this regard, albumin glycation alters the binding ability of albumin to other molecules [29,30]. Our in vitro analysis demonstrated that an increasing glycated albumin percentage in native albumin significantly reduced the ability of albumin to bind to the SARS-CoV-2 spike S1 subunit protein.…”